They analyzed the clinical benefits of the digital drug-assignment system using the data from the SHIVA01 precision oncology clinical trial, and showed that the system identified substantial molecular targets with the fitting inhibitors, including in lung cancer patients, such as FMS Related Receptor Tyrosine Kinase 3 mutation with sorafenib and Androgen receptor expression with abiraterone. The gene discussed is AR; the disease is lung cancer.